Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16920345 | 1.00 | CTSC (0.44) | CTSCGRIK1AGTR2GRIA2ALDH1A1 | |
| SCHEMBL1768681 | 1.00 | CTSC (0.44) | CTSCGRIK1AGTR2GRIA2ALDH1A1 | |
| SCHEMBL1006317 | 1.00 | CTSC (0.44) | CTSCGRIK1AGTR2GRIA2ALDH1A1 | |
| SCHEMBL6374726 | 1.00 | CTSC (0.44) | CTSCGRIK1AGTR2GRIA2ALDH1A1 | |
| SCHEMBL5802417 | 1.00 | CTSC (0.44) | CTSCGRIK1AGTR2GRIA2ALDH1A1 | |
| SCHEMBL1006316 | 1.00 | CTSC (0.44) | CTSCGRIK1AGTR2GRIA2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7449326 | 0.98 | GRIK1 (0.45) | CTSCGRIK1AGTR2GRIA2CTSL | |
| Hydrochloric Acid SCHEMBL5862746 | 0.98 | GRIK1 (0.45) | CTSCGRIK1AGTR2GRIA2CTSL | |
| Hydrochloric Acid SCHEMBL5862743 | 0.98 | GRIK1 (0.45) | CTSCGRIK1AGTR2GRIA2CTSL | |
| SCHEMBL8881468 | 0.93 | CTSC (0.40) | CTSCGRIK1AGTR2GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171495-A1 | MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION | WASHINGTON UNIVERSITY | 2025-05-29 | — | — | US | claimed |
| EP-4448547-A1 | APELINERGIC MACROCYCLES AND USES THEREOF | Socpra Sciences Santé Et Humaines S.E.C. (CA) | 2024-10-23 | — | — | EP | claimed |
| US-20240343761-A1 | APELINERGIC MACROCYCLES AND USES THEREOF | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2024-10-17 | — | — | US | claimed |
| US-12077611-B2 | Cyclic peptides multimers targeting α4β7 integrin | ZEALAND PHARMA A/S (DK) | 2024-09-03 | — | — | US | claimed |
| US-20230406884-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ZEALAND PHARMA A/S (DK) | 2023-12-21 | — | — | US | claimed |
| WO-2023108291-A9 | APELINERGIC MACROCYCLES AND USES THEREOF | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2023-09-28 | — | — | WO | claimed |
| US-11713338-B2 | Cyclic peptides multimers targeting α-4-β-7 integrin | ZEALAND PHARMA A/S (DK) | 2023-08-01 | — | — | US | claimed |
| WO-2023108291-A1 | APELINERGIC MACROCYCLES AND USES THEREOF | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2023-06-22 | — | — | WO | claimed |
| EP-4100040-A1 | DIAMINE-LINKED RECEPTOR-SPECIFIC CYCLIC PEPTIDES | Palatin Technologies, Inc. (US) | 2022-12-14 | — | — | EP | claimed |
| EP-4100042-A1 | REVERSE AMIDE-LINKED MELANOCORTIN RECEPTOR-SPECIFIC CYCLIC PEPTIDES | Palatin Technologies, Inc. (US) | 2022-12-14 | — | — | EP | claimed |
| US-20220363719-A1 | Reverse Amide-Linked Melanocortin Receptor-Specific Cyclic Peptides | PALATIN TECHNOLOGIES, INC. (US) | 2022-11-17 | — | — | US | claimed |
| WO-2026105061-A1 | ANTIBODY-DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | WO | disclosed |
| US-20260125418-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | OWLSTONE MED LTD (GB) | 2026-05-07 | — | — | US | disclosed |
| WO-2026090584-A2 | METHODS OF TREATING PERIPHERAL NERVOUS SYSTEM MYELINATION CONDITIONS | Artery Therapeutics, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731270-A1 | COMBINATION THERAPY WITH PEPTIDE RECEPTOR RADIONUCLIDE AND DNA REPAIR INHIBITOR | The Regents of The University of California (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20030055094-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2003-03-20 | — | — | US | disclosed |
| CN-1353701-A | Peptidyl heterocyclic ketones useful as tryptase inhibitors | ORTHO MCNEIL PHARM INC (US) | 2002-06-12 | — | — | CN | disclosed |
| US-6143715-A | FOR TREATING AND PREVENTION OF HEPATITIS C VIURS INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2000-11-07 | — | — | US | disclosed |
| WO-1995033763-A1 | NOVEL ELASTASE INHIBITORS | HOECHST MARION ROUSSEL, INC. (US) | 1995-12-14 | — | — | WO | disclosed |
| US-4316906-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171495-A1 | MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION | TMPRSS2, PRSS1, PRSS2 | CTSC 93/4885GRIK1 3611/4885AGTR2 1026/4885 |
| US-20220363719-A1 | Reverse Amide-Linked Melanocortin Receptor-Specific Cyclic Peptides | MC1R, NPY1R, MC3R | CTSC 1594/4885GRIK1 1049/4885AGTR2 358/4885 |
| US-20260125418-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | BRCA1, L3MBTL1, LMNA | CTSC 2040/4885GRIK1 4414/4885AGTR2 4162/4885 |
| US-20240343761-A1 | APELINERGIC MACROCYCLES AND USES THEREOF | APLNR, AP3D1, AP3B1 | CTSC 261/4885GRIK1 746/4885AGTR2 7/4885 |
| US-12077611-B2 | Cyclic peptides multimers targeting α4β7 integrin | ITGB7, ITGB4, ITGA4 | CTSC 1717/4885GRIK1 2361/4885AGTR2 2113/4885 |
| US-20030055094-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | CTSC 1726/4885GRIK1 1345/4885AGTR2 245/4885 |
| US-20230406884-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ITGB7, ITGB4, ITGA4 | CTSC 1174/4885GRIK1 2309/4885AGTR2 1642/4885 |
| US-11713338-B2 | Cyclic peptides multimers targeting α-4-β-7 integrin | ITGB7, ITGB4, ITGA4 | CTSC 1198/4885GRIK1 2404/4885AGTR2 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.